Barclays Maintains an 'Equalweight' on Biogen (BIIB); IMPACT RX Data Suggest Strong Gilenya Launch
Tweet Send to a Friend
Barclays maintains an 'Equalweight' on Biogen (NASDAQ: BIIB), PT $53.
Barclays analyst says, "We are maintaining our Equal Weight rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We are maintaining our Equal Weight rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
